Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Company initiates phase I clinical trial for anticancer compound XL820
August 25th, 2005
Exelixis, Inc., (EXEL) has initiated a phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetic profile of XL820, an orally administered, small-molecule anticancer compound. XL820 is a spectrum selective kinase inhibitor that simultaneously inhibits the receptor tyrosine kinases (RTKs) vascular endothelial growth factor, KIT, and platelet-derived growth factor, all of which are clinically validated targets implicated in a variety of human cancers. The phase I clinical trial is designed as an open-label, single and repeat dose-escalation study and will be conducted in patients with solid tumors for whom there are no available...
Source: Women's Health Weekly (2005-08-25)
|
